Literature DB >> 29299406

Avelumab-a new programmed death-ligand 1 inhibitor against advanced non-small cell lung cancer.

Ignacio Gil-Bazo1,2,3.   

Abstract

Entities:  

Year:  2017        PMID： 29299406      PMCID： PMC5750149          DOI： 10.21037/tlcr.2017.11.01

Source DB:  PubMed          Journal:  Transl Lung Cancer Res        ISSN： 2218-6751


× No keyword cloud information.
  16 in total

Review 1.  Interaction of PD-L1 on tumor cells with PD-1 on tumor-specific T cells as a mechanism of immune evasion: implications for tumor immunotherapy.

Authors:  Christian Blank; Thomas F Gajewski; Andreas Mackensen
Journal:  Cancer Immunol Immunother       Date:  2004-12-15       Impact factor: 6.968

2.  Atezolizumab versus docetaxel in patients with previously treated non-small-cell lung cancer (OAK): a phase 3, open-label, multicentre randomised controlled trial.

Authors:  Achim Rittmeyer; Fabrice Barlesi; Daniel Waterkamp; Keunchil Park; Fortunato Ciardiello; Joachim von Pawel; Shirish M Gadgeel; Toyoaki Hida; Dariusz M Kowalski; Manuel Cobo Dols; Diego L Cortinovis; Joseph Leach; Jonathan Polikoff; Carlos Barrios; Fairooz Kabbinavar; Osvaldo Arén Frontera; Filippo De Marinis; Hande Turna; Jong-Seok Lee; Marcus Ballinger; Marcin Kowanetz; Pei He; Daniel S Chen; Alan Sandler; David R Gandara
Journal:  Lancet       Date:  2016-12-13       Impact factor: 79.321

3.  Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial.

Authors:  Howard L Kaufman; Jeffery Russell; Omid Hamid; Shailender Bhatia; Patrick Terheyden; Sandra P D'Angelo; Kent C Shih; Céleste Lebbé; Gerald P Linette; Michele Milella; Isaac Brownell; Karl D Lewis; Jochen H Lorch; Kevin Chin; Lisa Mahnke; Anja von Heydebreck; Jean-Marie Cuillerot; Paul Nghiem
Journal:  Lancet Oncol       Date:  2016-09-01       Impact factor: 41.316

4.  Avelumab for patients with previously treated metastatic or recurrent non-small-cell lung cancer (JAVELIN Solid Tumor): dose-expansion cohort of a multicentre, open-label, phase 1b trial.

Authors:  James L Gulley; Arun Rajan; David R Spigel; Nicholas Iannotti; Jason Chandler; Deborah J L Wong; Joseph Leach; W Jeff Edenfield; Ding Wang; Hans Juergen Grote; Anja von Heydebreck; Kevin Chin; Jean-Marie Cuillerot; Karen Kelly
Journal:  Lancet Oncol       Date:  2017-03-31       Impact factor: 41.316

Review 5.  Checkpoints in lymphocyte development and autoimmune disease.

Authors:  Harald von Boehmer; Fritz Melchers
Journal:  Nat Immunol       Date:  2009-12-17       Impact factor: 25.606

6.  Durvalumab after Chemoradiotherapy in Stage III Non-Small-Cell Lung Cancer.

Authors:  Scott J Antonia; Augusto Villegas; Davey Daniel; David Vicente; Shuji Murakami; Rina Hui; Takashi Yokoi; Alberto Chiappori; Ki H Lee; Maike de Wit; Byoung C Cho; Maryam Bourhaba; Xavier Quantin; Takaaki Tokito; Tarek Mekhail; David Planchard; Young-Chul Kim; Christos S Karapetis; Sandrine Hiret; Gyula Ostoros; Kaoru Kubota; Jhanelle E Gray; Luis Paz-Ares; Javier de Castro Carpeño; Catherine Wadsworth; Giovanni Melillo; Haiyi Jiang; Yifan Huang; Phillip A Dennis; Mustafa Özgüroğlu
Journal:  N Engl J Med       Date:  2017-09-08       Impact factor: 91.245

7.  Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012.

Authors:  Jacques Ferlay; Isabelle Soerjomataram; Rajesh Dikshit; Sultan Eser; Colin Mathers; Marise Rebelo; Donald Maxwell Parkin; David Forman; Freddie Bray
Journal:  Int J Cancer       Date:  2014-10-09       Impact factor: 7.396

Review 8.  Programmed death ligand 2 in cancer-induced immune suppression.

Authors:  Esdy N Rozali; Stanleyson V Hato; Bruce W Robinson; Richard A Lake; W Joost Lesterhuis
Journal:  Clin Dev Immunol       Date:  2012-04-29

9.  A fully human IgG1 anti-PD-L1 MAb in an in vitro assay enhances antigen-specific T-cell responses.

Authors:  Italia Grenga; Renee N Donahue; Lauren M Lepone; Jacob Richards; Jeffrey Schlom
Journal:  Clin Transl Immunology       Date:  2016-05-20

10.  Analyses of the peripheral immunome following multiple administrations of avelumab, a human IgG1 anti-PD-L1 monoclonal antibody.

Authors:  Renee N Donahue; Lauren M Lepone; James L Gulley; Jeffrey Schlom; Italia Grenga; Caroline Jochems; Massimo Fantini; Ravi A Madan; Christopher R Heery
Journal:  J Immunother Cancer       Date:  2017-02-21       Impact factor: 13.751
View more
  2 in total

Review 1.  A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer.

Authors:  Yunes Panahi; Amir Hossein Mohammadzadeh; Behzad Behnam; Hossein M Orafai; Tannaz Jamialahmadi; Amirhossein Sahebkar
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 2.  Therapeutic and Systemic Adverse Events of Immune Checkpoint Inhibitors Targeting the PD-1/PD-L1 axis for Clinical Management of NSCLC.

Authors:  Jing Chen; Yaser Alduais; Baoan Chen
Journal:  Cell Transplant       Date:  2021 Jan-Dec       Impact factor: 4.064
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.